CA2343602A1 - Est et proteines humaines codees - Google Patents
Est et proteines humaines codees Download PDFInfo
- Publication number
- CA2343602A1 CA2343602A1 CA002343602A CA2343602A CA2343602A1 CA 2343602 A1 CA2343602 A1 CA 2343602A1 CA 002343602 A CA002343602 A CA 002343602A CA 2343602 A CA2343602 A CA 2343602A CA 2343602 A1 CA2343602 A1 CA 2343602A1
- Authority
- CA
- Canada
- Prior art keywords
- nos
- seq
- sequences
- sequence
- est
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Landscapes
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19787300P | 2000-04-18 | 2000-04-18 | |
| US60/197,873 | 2000-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2343602A1 true CA2343602A1 (fr) | 2001-10-18 |
Family
ID=22731080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002343602A Abandoned CA2343602A1 (fr) | 2000-04-18 | 2001-04-17 | Est et proteines humaines codees |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2343602A1 (fr) |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7365154B2 (en) * | 2003-06-23 | 2008-04-29 | Centocor, Inc. | Peptides antagonistic to an anti-angiogenic antibody and uses therefor |
| US7713521B2 (en) | 2005-08-12 | 2010-05-11 | Schering Corporation | MCP1 fusions |
| US8524217B2 (en) | 2010-05-11 | 2013-09-03 | Merck Sharp & Dohme Corp. | MCP1-Ig fusion variants |
| US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
| US9388215B2 (en) | 2013-03-15 | 2016-07-12 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
| US9758807B2 (en) | 2012-12-05 | 2017-09-12 | SOLA Biosciences, LLC | Protein expression enhancing polypeptides |
| WO2017173321A1 (fr) * | 2016-03-31 | 2017-10-05 | Neon Therapeutics, Inc. | Néoantigènes et leurs procédés d'utilisation |
| WO2017182395A1 (fr) * | 2016-04-21 | 2017-10-26 | Immatics Biotechnologies Gmbh | Immunothérapie contre le mélanome et d'autres cancers |
| CN110064045A (zh) * | 2019-05-15 | 2019-07-30 | 苏州大学 | 微肽cip2a-bp在治疗癌症中的应用 |
| US10435455B1 (en) | 2016-04-21 | 2019-10-08 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| US11793867B2 (en) | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
| AU2021244056B2 (en) * | 2020-03-27 | 2024-04-04 | Onecuregen Co., Ltd. | Composition comprising VGLL1 peptide for treatment of cancer |
| WO2024165674A1 (fr) * | 2023-02-08 | 2024-08-15 | Guard Therapeutics International AB | Fragments peptidiques dérivés de alpha-1-microglobuline et leurs utilisations |
| EP4279081A4 (fr) * | 2021-02-25 | 2024-11-13 | Hangzhou Huibo Science and Technology Co., Ltd | Utilisation de polypeptide pour favoriser la régénération ou la réparation du cartilage |
| US12246067B2 (en) | 2018-06-19 | 2025-03-11 | Biontech Us Inc. | Neoantigens and uses thereof |
| US12303561B2 (en) | 2017-04-03 | 2025-05-20 | Biontech Us Inc. | Protein antigens and uses thereof |
| WO2026047170A1 (fr) * | 2024-08-30 | 2026-03-05 | Aarhus Universitet | Fragments peptidiques n-terminaux pour la régulation du complément |
-
2001
- 2001-04-17 CA CA002343602A patent/CA2343602A1/fr not_active Abandoned
Cited By (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7365154B2 (en) * | 2003-06-23 | 2008-04-29 | Centocor, Inc. | Peptides antagonistic to an anti-angiogenic antibody and uses therefor |
| US7713521B2 (en) | 2005-08-12 | 2010-05-11 | Schering Corporation | MCP1 fusions |
| US7972591B2 (en) | 2005-08-12 | 2011-07-05 | Schering Corporation | Methods for treating rheumatoid arthritis and multiple sclerosis using MCP1 fusions |
| US8282914B2 (en) | 2005-08-12 | 2012-10-09 | Merck, Sharp & Dohme Corp. | Method for treating atherosclerosis by administering human MCP1 fusions |
| US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
| US8524217B2 (en) | 2010-05-11 | 2013-09-03 | Merck Sharp & Dohme Corp. | MCP1-Ig fusion variants |
| US9758807B2 (en) | 2012-12-05 | 2017-09-12 | SOLA Biosciences, LLC | Protein expression enhancing polypeptides |
| AU2013355120B2 (en) * | 2012-12-05 | 2017-11-09 | Sola Biosciences Llc | Protein expression enhancing polypeptides |
| US9388215B2 (en) | 2013-03-15 | 2016-07-12 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
| US9738695B2 (en) | 2013-03-15 | 2017-08-22 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
| US10899815B2 (en) | 2013-03-15 | 2021-01-26 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
| WO2017173321A1 (fr) * | 2016-03-31 | 2017-10-05 | Neon Therapeutics, Inc. | Néoantigènes et leurs procédés d'utilisation |
| US10385111B2 (en) | 2016-04-21 | 2019-08-20 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| US10519216B2 (en) | 2016-04-21 | 2019-12-31 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| WO2017182395A1 (fr) * | 2016-04-21 | 2017-10-26 | Immatics Biotechnologies Gmbh | Immunothérapie contre le mélanome et d'autres cancers |
| US10364281B2 (en) | 2016-04-21 | 2019-07-30 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| US9901629B2 (en) | 2016-04-21 | 2018-02-27 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| US10385110B2 (en) | 2016-04-21 | 2019-08-20 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| US10435454B2 (en) | 2016-04-21 | 2019-10-08 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| US10435455B1 (en) | 2016-04-21 | 2019-10-08 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| US10464991B2 (en) | 2016-04-21 | 2019-11-05 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| US10035838B2 (en) | 2016-04-21 | 2018-07-31 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| US10640547B2 (en) | 2016-04-21 | 2020-05-05 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| US12303561B2 (en) | 2017-04-03 | 2025-05-20 | Biontech Us Inc. | Protein antigens and uses thereof |
| US11793867B2 (en) | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
| US12246067B2 (en) | 2018-06-19 | 2025-03-11 | Biontech Us Inc. | Neoantigens and uses thereof |
| CN110064045A (zh) * | 2019-05-15 | 2019-07-30 | 苏州大学 | 微肽cip2a-bp在治疗癌症中的应用 |
| CN110064045B (zh) * | 2019-05-15 | 2022-12-23 | 苏州大学 | 微肽cip2a-bp在治疗癌症中的应用 |
| AU2021244056B2 (en) * | 2020-03-27 | 2024-04-04 | Onecuregen Co., Ltd. | Composition comprising VGLL1 peptide for treatment of cancer |
| EP4279081A4 (fr) * | 2021-02-25 | 2024-11-13 | Hangzhou Huibo Science and Technology Co., Ltd | Utilisation de polypeptide pour favoriser la régénération ou la réparation du cartilage |
| WO2024165674A1 (fr) * | 2023-02-08 | 2024-08-15 | Guard Therapeutics International AB | Fragments peptidiques dérivés de alpha-1-microglobuline et leurs utilisations |
| WO2026047170A1 (fr) * | 2024-08-30 | 2026-03-05 | Aarhus Universitet | Fragments peptidiques n-terminaux pour la régulation du complément |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7413875B2 (en) | ESTs and encoded human proteins | |
| US7235381B2 (en) | Expressed sequence tags and encoded human proteins | |
| US6936692B2 (en) | Complementary DNAs | |
| EP1033401A2 (fr) | Marqueurs de séquence exprimées et protéines humaines codées | |
| EP1037977B1 (fr) | ADNc PROLONGES POUR PROTEINES SECRETEES | |
| US7393663B2 (en) | Expressed sequence tags and encoded human proteins | |
| US20060223142A1 (en) | Extended cDNAs for secreted proteins | |
| US7056680B2 (en) | Antibodies to claudin-50 polypeptide | |
| CA2343602A1 (fr) | Est et proteines humaines codees | |
| WO2000037491A2 (fr) | Adn complementaires codant pour des proteines secretees avec des peptides signaux | |
| WO1999006439A2 (fr) | Est 5' pour proteines secretees exprimees dans l'endoderme | |
| EP1541683A1 (fr) | ESTs et leurs protéines codées humaines | |
| AU2002301051B9 (en) | Extended cDNAs for secreted proteins | |
| AU2003262114B2 (en) | cDNAs encoding secreted proteins | |
| AU2003204659B2 (en) | Extended cDNAs for secreted proteins | |
| EP1903111A2 (fr) | ADN étendus pour protéines secrétées | |
| AU1049199A (en) | Extended cdnas for secreted proteins | |
| AU2003262217A1 (en) | 5' ESTs and encoded human proteins | |
| AU2006225329A1 (en) | cDNAs encoding secreted proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |